The present invention relates to jelly beans wherein the amount of protein is at least 75% by weight and with a maximum amount of 18.69% carbohydrates, wherein the functional ingredients with a composition of: Proteins: 75-91.69%, Carbohydrates and/or sweeteners: 1-18.69%, Gelling agents: 1-10%, aromas: 0.01%-5%, colourings: 0.01%-5%, Functional (Food and Pharmaceutical) ingredients: 0.1-25%, Water: 5-25%, Acid: 0.1-5%, and PH correctors. The manufacturing method comprises the steps of: Preparing a base dough by mixing proteins and sugar Preparing an organoleptic dough Preparing a mixture of one or several functional ingredients Mixing of all previous doughs Depositing Drying Demoulding Packaging

Gummies are obtained having healthy functional ingredients, with a predominantly protein base of no less than 75% of the total composition and with a maximum of 18.69% carbohydrates that do not represent a significant alteration in the solubility of the dough and the pH.

In alternative embodiments, the invention provides a triple combination therapy for treating, ameliorating and preventing Crohn's Disease (or Crohn syndrome, terminal or distal ileitis or regional enteritis) or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, including genetically-predisposed and chronic disorders, where the microbial or bacterial flora of the bowel is at least one causative or symptom-producing factor; and compositions for practicing same. In alternative embodiments, methods and compositions of the invention comprise or comprise use of therapies, medications, formulations and pharmaceuticals comprising active agents that can suppress or eradicate the microbiota super-infection that causes Crohn's Disease or paratuberculosis infection in mammals. In alternative embodiments, the methods and uses of the invention for treating, ameliorating and preventing Crohn's Disease and complications of Crohn's Disease, or related disorders and conditions in mammals, such as paratuberculosis in mammals, or Johne's disease, comprises administration to an individual (human or mammal) in need thereof: (1) an anti-TNF? composition, or a composition capable of down-modulating TNF? activity; (2) a Hyperbaric Oxygen Treatment, or HBOT; and (3) an anti Mycobacterium avium sub species paratuberculosis (MAP) (an anti-MAP) agent, composition or therapy.

A dietary supplement composition having a dispersion including a plurality of liposomal vesicles, includes an active ingredient, phospholipid contained in the liposomal vesicles, and a coating material. The active ingredient is incorporated within the liposomal vesicles having a barrier coating of the coating material including one of a biopolymer, polyethylene glycol, chitosan and a combination thereof. The coating material is free flowing in the dispersion such that the liposomal vesicles are surrounded by the coating material without being attached to the liposomal vesicles and without forming part of the liposomal vesicles and without affecting weight of the liposomal vesicles. The dispersion is filtered using a tangential flow technique, which washes out outer periphery of liposomal vesicles for removing inactive ingredients contained outside the liposomal vesicles without washing out the coating material surrounding the liposomal vesicles. The dietary supplement composition may be incorporated in gummies, chocolates, atomizers or powders.

A method of making dietary supplement compositions includes generating an aqueous phase (A1) having one or more dietary supplement nutrients (DSN1), generating an oil phase (O1), performing a first homogenizing step by mixing A1 and O1 thereby forming A1/O1 composition, performing a second homogenizing step by mixing the A1/O1 composition and the further added DSN2, performing a third homogenizing step by mixing the A1/O1/DSN2 composition and a first flavor (F1), performing a fourth homogenizing step by mixing the A1/O1/DSN2/F1 composition and a gum dispersed with glycerin (GG), and performing a fifth homogenizing step by mixing the A1/O1/DSN2/F1/GG composition and the second flavor (F2) thereby forming dietary composition A1/O1/DSN2/F1/GG/F2. The A1/O1/DSN2/F1/GG/F2 composition is dispersion in which actives are incorporated in liposomal vesicles which may have a barrier coating of a polymer. A method of making gummies includes surrounding A1/O1/DSN2/F1/GG/F2 composition (inner portion) with an outer portion formed of shell syrup.

Synergistic composition comprising propolis and carnosic acid for use in the prevention and treatment of candidiasis. The invention relates to a synergistic composition comprising propolis that comprises polyphenols at a concentration between 70 and 90% by weight of propolis and carnosic acid, for use in the prevention and treatment of candidiasis in humans and/or animals. The invention also relates to a synergistic pharmaceutical and/or veterinary composition and a synergistic food product.

The present disclosure relates generally to oral compositions and methods for inhibiting the formation of plaque biofilm by salivary bacteria, and more particularly, to oral compositions comprising a combination of magnolia bark extract (MBE) and L-arginine, N.sup.-lauroyl ethyl ester (LAE). The oral compositions are useful for improving oral health, including inhibiting the formation of plaque biofilm by salivary bacteria and reducing plaque adherence to teeth.

Provided is an oral composition, including the following components (A), (B), and (C): (A) non-polymer catechins; (B) rutin; and (C) astragalin, wherein a content of the component (A) in solids is from 2 mass % to 50 mass %, wherein a mass ratio between the component (A) and the component (B), [(B)/(A)], is from 0.05?10.sup.?2 to 50?10.sup.?2, and wherein a mass ratio between the component (A) and the component (C), [(C)/(A)], is from 1.0?10.sup.?3 to 50?10.sup.?3.

The present invention relates to use of a composition comprising a panduratin derivative or a boesenbergia pandurata extract as an effective ingredient, which suppresses the differentiation of osteoclasts to exhibit the effect of treating, preventing or ameliorating bone loss diseases and which can be used safely as a natural material without side effects, thus finding effective applications in drugs, quasi-drugs, or foods.

Physiological cooling compounds of the structure: ##STR00001##
where R.sub.1 is p-menthyl or 2,3,4-trimethylpent-3-yl group and R.sub.2-R.sub.8 are hydrogen or alkyl groups. The combination of R.sub.2-R.sub.8 is such that the N-alkyl group is a branched C.sub.5 alkyl or branched or linear C.sub.6-C.sub.8 alkyl group. The new carboxamides are valuable sensory ingredients which provide long-lasting cooling sensation and freshness in personal care, oral care, cosmetic products, pharmaceutical preparations, confectionary, food and beverages.

A gummy composition, comprising a semi-solid chewable base comprising a gum composition, a gelling composition, and a bonding composition, wherein the gelling composition comprises a protein-based gelling agent, a carbohydrate-based gelling agent, or a combination thereof, wherein the gum composition and the gelling composition have a ratio of not more than 4:1 w/w, and wherein the bonding composition comprises a mono-, di- tri-, or oligosaccharide, a sugar alcohol, or a combination thereof.